FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204165999> ?p ?o ?g. }

• W3204165999 abstract "Background In event-driven clinical trials, study termination is based on accrual of a target number of primary efficacy events. For noninferiority trials in which superiority is conditionally examined, the ideal cohort in which to track event accrual is unclear. We used data from the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial to determine the effect of primary efficacy-event tracking in the per-protocol cohort during the on-treatment period versus the intention-to-treat (ITT) cohort during the ITT period. Methods and Results ROCKET AF was terminated after accruing 429 primary efficacy events (stroke or systemic embolism) in the per-protocol cohort during the on-treatment period for noninferiority. We identified the date on which 429 events occurred in the ITT cohort during the ITT period. We performed noninferiority and superiority analyses based on hypothetical study termination on this date. ROCKET AF would have terminated 226 days earlier if events were tracked during the ITT period. Similar to the main trial findings, rivaroxaban would have met noninferiority versus warfarin for the primary efficacy end point (hazard ratio [HR], 0.77; 95% CI, 0.62-0.96; P<0.001). In contrast to the main trial findings, rivaroxaban would have met superiority for the primary efficacy end point (HR, 0.82; 95% CI, 0.68-0.99; P=0.038). In both termination scenarios, rivaroxaban was associated with a lower risk of intracranial hemorrhage and similar risk of other safety end points. Conclusions Clinical trial termination based on event accrual in the ITT cohort versus the per-protocol cohort may have important implications on trial results depending on rates of study drug discontinuation and event rates off treatment." @default.
• W3204165999 created "2021-10-11" @default.
• W3204165999 creator A5004956623 @default.
• W3204165999 creator A5014777482 @default.
• W3204165999 creator A5014800121 @default.
• W3204165999 creator A5017529464 @default.
• W3204165999 creator A5020290782 @default.
• W3204165999 creator A5023346746 @default.
• W3204165999 creator A5036147033 @default.
• W3204165999 creator A5039432822 @default.
• W3204165999 creator A5048892710 @default.
• W3204165999 creator A5053251076 @default.
• W3204165999 creator A5055052720 @default.
• W3204165999 creator A5060254903 @default.
• W3204165999 creator A5060829829 @default.
• W3204165999 creator A5086040903 @default.
• W3204165999 date "2021-10-05" @default.
• W3204165999 modified "2023-10-06" @default.
• W3204165999 title "Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial" @default.
• W3204165999 cites W1965320794 @default.
• W3204165999 cites W1997539987 @default.
• W3204165999 cites W2083035480 @default.
• W3204165999 cites W2096246254 @default.
• W3204165999 cites W2097854437 @default.
• W3204165999 cites W2118857793 @default.
• W3204165999 cites W2135241452 @default.
• W3204165999 cites W2162508946 @default.
• W3204165999 cites W2273267066 @default.
• W3204165999 cites W2557845780 @default.
• W3204165999 cites W3038460242 @default.
• W3204165999 cites W3086908893 @default.
• W3204165999 cites W3388698 @default.
• W3204165999 doi "https://doi.org/10.1161/jaha.121.022485" @default.
• W3204165999 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34569249" @default.
• W3204165999 hasPublicationYear "2021" @default.
• W3204165999 type Work @default.
• W3204165999 sameAs 3204165999 @default.
• W3204165999 citedByCount "0" @default.
• W3204165999 crossrefType "journal-article" @default.
• W3204165999 hasAuthorship W3204165999A5004956623 @default.
• W3204165999 hasAuthorship W3204165999A5014777482 @default.
• W3204165999 hasAuthorship W3204165999A5014800121 @default.
• W3204165999 hasAuthorship W3204165999A5017529464 @default.
• W3204165999 hasAuthorship W3204165999A5020290782 @default.
• W3204165999 hasAuthorship W3204165999A5023346746 @default.
• W3204165999 hasAuthorship W3204165999A5036147033 @default.
• W3204165999 hasAuthorship W3204165999A5039432822 @default.
• W3204165999 hasAuthorship W3204165999A5048892710 @default.
• W3204165999 hasAuthorship W3204165999A5053251076 @default.
• W3204165999 hasAuthorship W3204165999A5055052720 @default.
• W3204165999 hasAuthorship W3204165999A5060254903 @default.
• W3204165999 hasAuthorship W3204165999A5060829829 @default.
• W3204165999 hasAuthorship W3204165999A5086040903 @default.
• W3204165999 hasBestOaLocation W32041659991 @default.
• W3204165999 hasConcept C126322002 @default.
• W3204165999 hasConcept C127413603 @default.
• W3204165999 hasConcept C141071460 @default.
• W3204165999 hasConcept C168563851 @default.
• W3204165999 hasConcept C201903717 @default.
• W3204165999 hasConcept C203092338 @default.
• W3204165999 hasConcept C207103383 @default.
• W3204165999 hasConcept C2776301958 @default.
• W3204165999 hasConcept C2778661090 @default.
• W3204165999 hasConcept C2779161974 @default.
• W3204165999 hasConcept C2780645631 @default.
• W3204165999 hasConcept C44249647 @default.
• W3204165999 hasConcept C535046627 @default.
• W3204165999 hasConcept C71924100 @default.
• W3204165999 hasConcept C72563966 @default.
• W3204165999 hasConcept C78519656 @default.
• W3204165999 hasConceptScore W3204165999C126322002 @default.
• W3204165999 hasConceptScore W3204165999C127413603 @default.
• W3204165999 hasConceptScore W3204165999C141071460 @default.
• W3204165999 hasConceptScore W3204165999C168563851 @default.
• W3204165999 hasConceptScore W3204165999C201903717 @default.
• W3204165999 hasConceptScore W3204165999C203092338 @default.
• W3204165999 hasConceptScore W3204165999C207103383 @default.
• W3204165999 hasConceptScore W3204165999C2776301958 @default.
• W3204165999 hasConceptScore W3204165999C2778661090 @default.
• W3204165999 hasConceptScore W3204165999C2779161974 @default.
• W3204165999 hasConceptScore W3204165999C2780645631 @default.
• W3204165999 hasConceptScore W3204165999C44249647 @default.
• W3204165999 hasConceptScore W3204165999C535046627 @default.
• W3204165999 hasConceptScore W3204165999C71924100 @default.
• W3204165999 hasConceptScore W3204165999C72563966 @default.
• W3204165999 hasConceptScore W3204165999C78519656 @default.
• W3204165999 hasIssue "19" @default.
• W3204165999 hasLocation W32041659991 @default.
• W3204165999 hasLocation W32041659992 @default.
• W3204165999 hasLocation W32041659993 @default.
• W3204165999 hasOpenAccess W3204165999 @default.
• W3204165999 hasPrimaryLocation W32041659991 @default.
• W3204165999 hasRelatedWork W1907038671 @default.
• W3204165999 hasRelatedWork W2021252689 @default.
• W3204165999 hasRelatedWork W2101093423 @default.
• W3204165999 hasRelatedWork W2168788799 @default.
• W3204165999 hasRelatedWork W2397154677 @default.
• W3204165999 hasRelatedWork W2606162097 @default.
• W3204165999 hasRelatedWork W2888986290 @default.
• W3204165999 hasRelatedWork W2920404400 @default.

• next